Exclusivity 'Didn't Require Success,' Amgen Tells DC Circ.

Amgen told a D.C. Circuit panel Thursday that it's entitled to extra exclusivity protection for its lucrative calcium-control drug Sensipar because it fulfilled the U.S. Food and Drug Administration's request to...

Already a subscriber? Click here to view full article